JHS Svendgaard Laboratories Intrinsic Value
JHS Svendgaard Laboratories intrinsic value. JHS Svendgaard Laboratories (JHS) median intrinsic value is ₹5.52 from 7 valuation models (range ₹4–₹20), vs current price ₹11.70 — -52.8% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse JHS FII DII holdings to track promoter, FII and institutional holdings.
JHS Valuation Methods Summary — DCF, Graham Number & P/E
JHS Svendgaard Laboratories intrinsic value across 7 models vs current price ₹11.70 — upside/downside and value range per method. Browse JHS cash flow statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹3.51 | ₹2.81 - ₹4.21 | -70.0% | EPS: ₹0.24, Sector P/E: 12x |
| Book Value Method | asset | ₹20.11 | ₹18.10 - ₹22.12 | +71.9% | Book Value/Share: ₹20.11, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹8.46 | ₹7.61 - ₹9.31 | -27.7% | Revenue/Share: ₹10.57, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹5.52 | ₹4.97 - ₹6.07 | -52.8% | EBITDA: ₹8.00Cr, EV/EBITDA: 6x |
| PEG Ratio Method | growth | ₹3.51 | ₹3.16 - ₹3.86 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹3.51 | ₹3.16 - ₹3.86 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹10.42 | ₹9.38 - ₹11.46 | -10.9% | EPS: ₹0.24, BVPS: ₹20.11 |
JHS Intrinsic Value vs Market Price — All Valuation Models
JHS Svendgaard Laboratories fair value range ₹4–₹20 vs current market price ₹11.70 across 7 valuation models. For current market price and key ratios, visit JHS share price screener.
JHS Intrinsic Value Analysis — Undervalued or Overvalued?
JHS Svendgaard Laboratories median intrinsic value ₹5.52, current price ₹11.70 — Trading Above Calculated Value by 52.8%, margin of safety -100.0%.
What is the intrinsic value of JHS?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of JHS Svendgaard Laboratories (JHS) is ₹5.52 (median value). With the current market price of ₹11.70, this represents a -52.8% variance from our estimated fair value.
The valuation range spans from ₹3.51 to ₹20.11, indicating ₹3.51 - ₹20.11.
Is JHS undervalued or overvalued?
Based on our multi-method analysis, JHS Svendgaard Laboratories (JHS) appears to be trading above calculated value by approximately 52.8%.
JHS Financial Health — Key Ratios vs Industry Benchmarks
JHS Svendgaard Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 2.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 2.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.43x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
JHS Cash Flow Quality — Operating & Free Cash Flow
JHS Svendgaard Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-3 Cr | ₹-9 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-5 Cr | ₹-15 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-9 Cr | ₹-20 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹23 Cr | ₹23 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-9 Cr | ₹-12 Cr | Negative Cash Flow | 3/10 |